


JEEVAN SCIENTIFIC TECHNOLOGY LIMITED
Registered Office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Hyderabad-500008.
STAND ALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH 2017

Sl.No	Particulars	Rupees in lakhs				
		3 months ended	Preceding 3 months ended	Corresponding 3 months in the previous year	Year to date figures for the Current Period ended	Previous Year ended
		31-03-2017 Audited	31-12-2016 Un Audited	31-03-2016 Audited	31-03-2017 Audited	31-03-2016 Audited
1	Income from Operations					
	(a) Net Sales/Income from Operations (Net of excise duty)					
	(b) Other Operating Income	506.64	410.59	374.18	1,746.06	1733.69
	Total income from Operations (net)	506.64	410.59	374.18	1,746.06	1,733.69
2	Expenses					
	(a) Cost of Material Consumed	4.22	2.23	15.10	15.85	15.10
	(b) Purchase of stock-in-trade	-	-	-	-	-
	(c) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-
	(d) Employee benefit expense	67.02	33.93	54.00	186.34	324.92
	(e) Depreciation and Amortisation expense	34.71	28.68	26.01	118.09	67.14
	(f) Other Expenses (Any item exceeding 10% of the total Expenses relating to continuing operations to be shown separately)	352.23	290.38	326.97	1,233.44	1,184.92
	Total Expenses	458.18	355.22	422.08	1,553.72	1,592.08
3	Profit / (Loss) from operations before Other Income, finance costs and exceptional items(1-2)	48.46	55.37	-47.90	192.34	141.61
4	Other Income	27.38	11.05	16.24	56.99	40.32
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3+4)	75.84	66.42	-31.66	249.33	181.93
6	Finance Costs	26.30	31.40	37.26	127.27	117.69
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5-6)	49.54	35.02	-68.92	122.06	64.24
8	Exceptional Items	-	(11.29)	-	(11.29)	-
9	Profit / (Loss) from ordinary activities before Tax (7+8)	49.54	23.73	-68.92	110.77	64.24
10	Tax Expense	(2.04)	4.52	(4.85)	9.63	22.30
11	Net Profit / (Loss) from ordinary activities after Tax (9-10)	51.58	19.21	-64.07	101.14	41.94
12	Extraordinary items (Net of Tax Expense)	-	-	-	-	-
13	Net Profit / (Loss) for the Period (11-12)	51.58	19.21	-64.07	101.14	41.94



14	Share of Profit / (Loss) of associates*	-	-	-	-	-
15	Minority Interest*	-	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15)	51.58	19.21	-64.07	101.14	41.94
17	Paid Up Equity Share Capital (Face Value of Rs.10/- each)	927.95	811.45	604.16	927.95	604.16
18	Reserves excluding Revaluation Reserves as per balance sheet of Previous accounting year	-	-	-	572.30	(184.51)
19	i. Earnings per share (before extraordinary items) Basic and diluted	0.56	0.24	-1.06	1.09	0.69
	ii. Earnings per share (after extraordinary items) Basic and diluted	0.56	0.24	-1.06	1.09	0.69

* Applicable in the case of consolidated financial results.

Notes: (1) The above Audited Financial Results were reviewed by the Audit Committee and approved by the Board of Directors at their Meeting held on 30.05.2017

(2) Figures have been regrouped wherever necessary.

Place:Hyderabad

Date: 30.05.2017



SEGMENT-WISE REVENUE, RESULTS & CAPITAL EMPLOYED (Stand Alone Auudited)
UNDER CLAUSE 41 OF THE LISTING AGREEMENT FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2017

Particulars	Rupees in lakhs				
	3 months ended	Preceding 3 months ended	Corresponding 3 months in the previous year	Year to date figures for the Current Period ended	Previous Year ended
	31-03-2017 Audited	31-12-2016 Un Audited	31-03-2016 Audited	31-03-2017 Audited	31-03-2016 Audited
SEGMENT REVENUE: (Net Sales / Income from Operations)					
a) Clinical Research Services	120.21	72.92	37.82	347.09	96.52
b) Information Technology Services	68.25	16.88	-	118.63	378.01
c) Data Management Services	318.18	320.79	336.35	1,280.34	1,259.16
d) Unallocable income	27.38	11.05	16.24	56.99	40.32
Total:	534.02	421.64	390.41	1,803.05	1,774.01
LESS: Inter Segment revenue	-	-	-	-	-
Net Sales/income from Operations.	534.02	421.64	390.41	1,803.05	1,774.01
SEGMENT RESULTS : PROFIT / (LOSS) BEFORE TAX AND INTEREST					
a) Clinical Research Services	-44.71	-16.20	-115.25	-126.23	-394.82
b) Information Technology Services	46.69	3.80	-	70.32	266.42
c) Data Management Services	56.79	67.77	70.14	258.56	272.79
Total:	58.77	55.37	-45.11	202.65	144.39
LESS:					
i) Interest	26.30	31.40	37.27	127.27	117.69
ii) Other Un-Allocable Expenditure	10.31	11.29	2.78	21.60	2.78
iii) Un-Allocable Income	-27.38	-11.05	-16.24	-56.99	-40.32
TOTAL PROFIT /(-LOSS) BEFORE TAX	49.54	23.73	-68.92	110.77	64.24

NOTES:

i) Segment Capital Employed: Fixed Assets used in the Company's business have been identified and only computers, software and work stations are shared among different segments.



Stand Alone Balance Sheet as at 31st March, 2017		
(In Rupees)		
Particulars	As at 31.03.2017	As at 31.03.2016
I. Equity and Liabilities		
(1) Shareholders' Funds		
a) Share Capital	9,27,94,650	6,04,16,000
b) Reserves and surplus	5,72,30,354	-1,84,50,629
c) Money Received Against share Warrants	4,76,04,502	-
(2) Non-current Liabilities		
a) Long term borrowings	4,74,75,165	8,31,93,804
b) Long-term provisions	7,46,915	2,71,264
(3) Current Liabilities		
a) Short term borrowings	2,46,21,966	2,44,79,407
b) Trade Payables	1,66,45,865	3,01,64,207
c) Other current liabilities	3,89,18,357	2,23,80,034
d) Short term provisions	71,10,645	32,95,989
Total	33,31,48,419	20,57,50,076
II. Assets		
(1) Non-current Assets		
a) Fixed Assets		
i) Tangible Assets	10,52,29,694	8,10,22,897
ii) Intangible Assets	3,30,70,949	49,87,545
b) Non Current Investments	52,69,070	52,69,070
c) Deferred tax asset (net)	12,81,864	22,44,508
d) Long-term loans and advances	3,01,40,132	53,01,597
(2) Current Assets		
a) Inventories	2,67,96,786	2,27,97,681
b) Trade receivables	11,10,69,188	7,22,64,103
c) Cash and bank balances	19,68,896	16,57,772
e) Other Current Assets	1,83,21,840	1,02,04,903
Total	33,31,48,419	20,57,50,076

Place: Hyderabad
Date: 30.05.2017

for Jeevan Scientific Technology Limited
On behalf of the Board of Directors


K. Krishna Kishore
Vice Chairman & Managing Director

